The Heart of the Matter: An Update on Hypertrophic Cardiomyopathy
This CPE activity will: provide an Overview of hypertrophic cardiomyopathy disease state, review of present guideline-based approaches to treatment, and evaluation of new drug therapy.
This conference is being held virtually.
Target Audience
This course is intended for pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to
- Distinguish hypertrophic cardiomyopathy from other types of heart failure
- Summarize current guideline-based recommendations for the treatment of hypertrophic cardiomyopathy
- Create a guideline-supported treatment plan for a patient case of hypertrophic cardiomyopathy
- Evaluate the role of mavacamten in the treatment of hypertrophic cardiomyopathy
Faculty
Adam Wargolet, PharmD PGY1 Pharmacy Resident - Aurora Health Care Metro, Inc.
Disclosure
The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.
1 contact hour of continuing pharmacy education (0.1 CEU) is available for pharmacist participants.
Available Credit
- 1.00 Continuing Pharmacy Education (CPE)Aurora Health Care Department of Pharmacy Services is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Price
Click “Take Course” to register for this program.
This conference is being held virtually. A link to the meeting will be provided prior to the event.
Contact the AAH Pharmacy Continuing Education team at AAH-PharmacyCPEsubmission@aah.org if you have any questions or need assistance.